Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Phenylacetylglutamine (PAG) is a gut microbiota-dependent metabolite associated with cardiovascular diseases (CVD). Research has shown that Phenylacetylglutamine (PAG) is linked to atherothrombotic heart disease and heart failure, and it acts via adrenergic receptors, contributing to Cardiovascular Diseases (CVD) and thrombosis potential. The metabolite is associated with declining left ventricular ejection fraction (LVEF), indicating a potential association with heart failure severity. These findings suggest that Phenylacetylglutamine (PAG) may serve as a p…